Eli Lilly & Co.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5324571083
USD
1,014.49
-19.07 (-1.85%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Eli Lilly & Co. stock-summary
stock-summary
Eli Lilly & Co.
Pharmaceuticals & Biotechnology
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Company Coordinates stock-summary
Company Details
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr INDIANAPOLIS IN : 46285-0001
stock-summary
Tel: 1 317 2762000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 280 Schemes (29.65%)

Foreign Institutions

Held by 763 Foreign Institutions (13.43%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. David Ricks
Chairman of the Board, President, Chief Executive Officer
Mr. Juan Luciano
Lead Independent Director
Mr. Raul Alvarez
Independent Director
Dr. Katherine Baicker
Independent Director
Dr. Carolyn Bertozzi
Independent Director
Mr. Michael Eskew
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
15,558 Million
(Quarterly Results - Jun 2025)
Net Profit:
5,660 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 699,433 Million (Large Cap)

stock-summary
P/E

47.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.99

stock-summary
Return on Equity

93.61%

stock-summary
Price to Book

38.28